-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: CSF Tau
Further Dementia Diagnostic Test Accuracy Systematic Review Protocols (Cochrane Database)
Summary This is an additional list of diagnostic testing-related protocols, further to the Cochrane Dementia and Cognitive Improvement Group (CDCIG) Diagnostic Test Accuracy (DTA) protocols and protocol templates listed earlier in Generic Protocol(s) for Diagnostic Test Accuracy Reviews in Dementia … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Models of Dementia Care, NIHR, Systematic Reviews, UK
|
Tagged 11C-PIB-PET, 18FDG-PET, 6-Item Cognitive Impairment Test (6-CIT), Abbreviated Mental Test (AMT), Addenbrooke's Cognitive Exaination-Revised (ACE-R), ALOIS: the Cochrane Dementia and Cognitive Improvement Group, APOE e4 (Apolipoprotein E e4), APOE-4 Allele, Asymptomatic Alzheimer’s Disease, Blessed Information-Memory-Concentration Test (Blessed I-M-C), Brain Imaging, Bristol University, Canada, CDCIG: Cochrane Dementia and Cognitive Improvement Group, Central and North West London NHS Foundation Trust, China, China Medical University, Clinical Cooperation Unit Nuclear Medicine (Heidelberg), Clock Drawing Test (CDT), Cochrane Dementia and Cognitive Improvement Group (CDCIG), Cochrane Diagnostic Test Accuracy (DTA) Dementia Reviews, Cochrane Diagnostic Test Accuracy (DTA) Reviews, Cochrane Diagnostic Test Accuracy Review Unit (DTA Unit), Cognitive Assessments / Screening Tools, CSF (Cerebrospinal Fluid Analysis of Amyloid Beta and Tau), CSF Tau, CSF Tau / ABeta Ratio, Department of Neurology: VU University Medical Centre Amsterdam, Devon, Diagnostic Test Accuracy (DTA) Handbook, Diagnostic Test Accuracy Reviews, Differential Diagnosis, Differential Diagnosis of Alzheimer’s Disease, Dopamine Transporter Imaging, Dopamine Transporter Imaging (for Diagnosis of DLB), DTA Handbook, Early Differential Diagnosis, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta: Neuroepidemiology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, FP-CIT (Fluoropropyl-Carbomethoxy-3b-(4-Iodophenyl)Tropane), Frenchay Hospital (Bristol), Frontotemporal Dementia (FTD), Generic Protocols for Cross-Sectional and Delayed-Verification Studies, German Cancer Research Center: Medical PET Group - Biological Imaging, Germany, Glasgow Royal Infirmary, GP-Cog, Imaging, Imperial College London, Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Institute of Cardiovascular and Medical Sciences: Glasgow, Institute of Cardiovascular and Medical Sciences: University of Glasgow, Institute of Health Research: Exeter, Institute of Public Health (Cambridge UK), Institute of Public Health (IPH), Institute of Public Health: Cambridge, IRCCS Fatebenefratelli (Brescia), Italy, John Radcliffe Hospital, LITA Polo Universitario, Maastricht University, Maastricht University: Department of Psychiatry and Neuropsychology, Mini-Cog, Modified Mini-Mental State Examination (3-MS), MRI, MRI Brain Imaging, MRI Scans, National Institute for Health Research (NIHR) Cochrane Collaboration Programme, Netherlands, Neuroimaging in Dementia Diagnosis, Neuropsychological Tests for Alzheimer’s Disease Diagnosis, Neuropsychological Tests for Dementia Diagnosis, North Bristol NHS Trust, Nuffield Department of Clinical Neurosciences (Oxford), Nuffield Department of Clinical Neurosciences: University of Oxford, Nuffield Department of Medicine (Oxford), Older People and Healthy Ageing Service Line (London), OPTIMA (Oxford Project to Investigate Memory and Ageing), OPTIMA (Oxfordshire UK), Ospedale Luigi Sacco, Oxford, Oxford Health NHS Foundation Trust, Oxford University Hospitals NHS Trust, Oxford University Medical School, PenCLAHRC, Peninsula CLAHRC, Peninsula Technology Assessment Group (PenTAG), PET-FDG (Positron Emission Tomography F-Fluorodeoxyglucose), PET-PiB (Positron Emission Tomography-Pittsburgh Compound B), Plasma and Cerebrospinal Fluid (CSF) Abeta42, Positron Emission Tomography (PET), Protocols, Public Health Epidemiology and Biostatistics: Birmingham, Queen's University (Canada), Radcliffe Department of Medicine, ratio, rCBF SPECT, Research Protocol, School for Mental Health and Neuroscience: Maastricht University, Shengjing Hospital, sMRI (Structural Magnetic Resonance Imaging), SPECT (Single Photon Emission Computed Tomography), St Louis University Mental Status Examination (SLUMS), Study Protocol, Sunnybrook Health Sciences Centre (Toronto), Systematic Reviews and Meta-Analyses, Test Your Memory (TYM), University Hospitals Bristol, University of Birmingham, University of Bristol, University of Cambridge, University of Exeter, University of Exeter Medical School, University of Glasgow, University of Milan, University of Oxford, University of Toronto, VU University (Netherlands), VU University Medical Centre
|
Leave a comment
Recent Brain Research / Neurology-Related Systematic Reviews and Meta-Analyses
Summary Recent reviews and meta-analyses on neurology-related topics are listed below. Some of these articles may be available freely (according to local circumstances). A suitable Athens password, a journal subscription or payment for access are required to obtain the full-text … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), International, Systematic Reviews
|
Tagged Adult-Onset Spinocerebellar Ataxias, Biomarkers, Cerebrospinal Fluid (CSF), Charles Bonnet Syndrome, Chemokine Receptors, Chemokines, Chronic Traumatic Encephalopathy, Cognitive Decline, CSF Tau, DaTSCAN, Dementia with Lewy Bodies, DLB: Dementia with Lewy Bodies, Dorsal Angular Gyrus, Frontotemporal Dementia (FTD), Homocysteine, Hyperconnectivity, Neurodegeneration, Neurodegenerative Diseases, Neurological Disease, Neurological Research, Neuropathology, Neurosonology, Perturbed Iron Distribution, Posterior Middle Temporal Cortex, Primary Progressive Aphasia (PPA)
|
Leave a comment
Concerning the Diagnostic Accuracy of Plasma and CSF Biomarkers (Cochrane Database)
Summary This systematic review investigates the diagnostic accuracy of blood plasma and CSF Aß levels for detecting patients with mild cognitive impairment (MCI) and who are likely to progress to Alzheimer’s Disease or other types of dementia. The accuracy of … Continue reading →
Posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews, UK
|
Tagged Aß40, Aß42, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Alzheimer's Association, Alzheimer's Disease and Related Disorders Association (Now the Alzheimer's Association), Alzheimer’s Disease Biomarkers, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Apolipoprotein E, Asymptomatic Alzheimer’s Disease, Beta-Amyloid, Beta-Amyloid Plaques, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood-Based Biomarkers, Cambridge Institute of Public Health, Cambridge Institute of Public Health: Cambridge University, Candidate Blood Proteome Markers, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cochrane Database, Cochrane Database of Systematic Reviews, Cochrane Dementia and Cognitive Improvement Group, Cochrane Register of Diagnostic Test Accuracy Studies, Cognitive Impairment, Cognitive Response to Progression of Pathophysiology, Conversion to Dementia From Prodromal Disease, CSF Aß Levels, CSF Aβ, CSF Biomarkers, CSF Tau, Dementia Screening, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV), Diagnostic Test Accuracy, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Differential Diagnosis, Early Screening, Fluid and Imaging Biomarkers, Imperial College London, Institute of Public Health: University of Cambridge, β-amyloid, β-Amyloid 1-42 (Aβ42), MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), National Institute of Neurological and Communicative Disorders and Stroke, Neurodegeneration, NINCDS-ADRDA Criteria, NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association, Plasma Biomarkers, Plasma Proteins, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Progression of Mild Cognitive Impairment to Dementia, Systematic Reviews and Meta-Analyses, Transition from Cognitive Impairment to Dementia, University of Birmingham, University of Cambridge, University of Oxford, University of Oxford: Radcliffe Department of Medicine, University of Western Australia, US Alzheimer's Association, Western Australian Centre for Health and Ageing (WACHA)
|
Leave a comment
Alzheimer’s Disease Biomarkers: Updated Hypothetical Model (Lancet Neurology)
Summary A hypothetical model of the major biomarkers of Alzheimer’s Disease, published by the same authors in 2010, has been updated in the light of new evidence. Full Text Link Reference Jack, CR. Jr. Knopman, DS. [and] Jagust, WJ. [et … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews
|
Tagged Aβ, Aβopathy, Aβopathy Acceleration of Antecedent Tauopathy, Alzheimer's Disease: Hypothetical Model(s), Alzheimer’s Disease Biomarkers, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Apolipoprotein E, Beta-Amyloid, Beta-Amyloid Plaques, Biomarker Assessments in Alzheimer’s Disease, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Brain Beta Amyloid Load, Brain Deposition of Amyloid, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Clearance of Amyloid Beta Protein, Cognitive Impairment, Cognitive Response to Progression of Pathophysiology, CSF Aβ, CSF Biomarkers, CSF Tau, Department of Biomedical Statistics and Informatics: Mayo Clinic (Rochester), Department of Neurology: Mayo Clinic (Rochester), Department of Neurosciences: University of California-San Diego, Department of Radiology: Mayo Clinic (Rochester), Early Detection of Alzheimer’s Disease, Early Diagnosis of Alzheimer's Disease, Fluid and Imaging Biomarkers, Indexing Subjects by Time, Inter-Subject Variability, β-amyloid, β-Amyloid 1-42 (Aβ42), Lancet Neurology, Longitudinal Population Studies of Diagnostic Biomarkers, Mayo Clinic: Rochester, Metabolic FDG-PET, Molecular PIB-PET, Neurodegeneration, Neurofibrillary Tangles (NFTs), Neuroimaging, Neuroimaging of Dementia, Neuroimaging Tools, Ordering of Alzheimer's Disease Biomarkers, Pathophysiological Processes in Alzheimer’s Disease, Positron Emission Tomography (PET), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Proteinopathies, School of Public Health and Helen Wills Neuroscience Institute: University of California, Sequence of Pathological Events in Alzheimer’s Disease, Structural MRI, Tau, Tau Pathology, Tau Protein, Temporal Evolution of Alzheimer’s Disease Biomarkers, Temporal Ordering of Biomarkers, Test to Detect Early-Stage Alzheimer’s Disease, United States, University of California, University of Pathology and Laboratory Medicine and Institute on Aging: University of Pennsylvania, University of Pennsylvania School of Medicine, USA, Veterans Affairs and University of California
|
Leave a comment
Early Diagnosis of Alzheimer’s Disease Using Spinal Fluid? (NHS Choices / Cell Reports)
Summary A recent diagnostic study has investigated the possibility of diagnosing Alzheimer’s Disease, years before disease onset, using cerebrospinal fluid (CSF). The technique for identifying people with Alzheimer’s Disease would be based on detecting very small amounts of abnormal (misfolded) … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest
|
Tagged Aβ-PMCA, Alzheimer's Association, Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amprion Inc., Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Assessment and Diagnosis, Behind the Headlines, Beta-Amyloid, Beta-Amyloid Plaques, Biochemical Diagnosis of Alzheimer's Disease, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Carlo Besta Neurological Institute, CART Foundation, Cell Reports, Centro Dino Ferrari, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, CSF, CSF Aβ, CSF Aβ(1-42), CSF Biomarkers, CSF Tau, Cyclic Amplification of Amyloid-Beta Misfolding, Dementia Screening, Department of Neurology: University of Texas Medical School at Houston, Detection of Synthetic Ab Oligomers by Ab-PMCA, Differential Diagnosis, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Screening, Improving Diagnosis, IRCC Ospedale Policlinico, IRCCS Foundation, Italian Ministry of Health, Italy, Lumbar Punctures, Milan, Misfolded Aβ Oligomers, Misfolded Proteins, Mitchell Center for Alzheimer's Disease and Related Brain Disorders: University of Texas Medical School at Houston, Mitchell Foundation, MIUR, Neurodegeneration, Neurodegenerative Diseases, Neurology Unit: Università di Milano, Non-AD Neurodegenerative Diseases (NANDs), Nondegenerative Neurological Diseases (NNDs), Protein Misfolding Cyclic Amplification (PMCA), Screening, Spinal Fluid, Timely Diagnosis, Università di Milano, University of Texas Medical School at Houston, USA
|
Leave a comment
Biomarker Assessments in Alzheimer’s Disease Clinical Trials (Quintiles / Frontiers in Aging Neuroscience)
Summary Accurate and sensitive tools are required for the early detection / diagnosis of Alzheimer’s Disease, particularly to assist research. Alzheimer’s Disease clinical trials make increasing use of biomarkers, particularly neuroimaging markers and cerebrospinal fluid (CSF) biomarkers obtained via invasive … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Quick Insights
|
Tagged Aβ42, Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort, Alzheimer’s Disease Clinical Trials, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Argentina, Australia, Autonomous Systems Laboratory: Universidad Politécnica de Madrid, Avid’s AV-45 (Florbetapir), Belgium, Beta-Amyloid, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomedical Engineering Laboratory: Okayama University, BM List of AD Biomarkers, BM=(w o τ aβ hc fc tac), Canada, Cerebrospinal Fluid (CSF), Chile, Clearance of Amyloid Beta Protein, Compliance with Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Computed Tomography (CT), CSF, CSF Aβ, CSF Aβ(1-42), CSF Tau, Default-Mode Network (DMN), Dementia Research, Denmark, Disease Progression, Finland, Fludeoxyglucose FDG PET, Flutemetamol (18F), fMRI, France, Frontiers in Aging Neuroscience, Functional Connectivity, Functional Magnetic Resonance Imaging (fMRI), GE’s Flutametamol, Germany, Global Alzheimer’s Association Interactive Network (GAAIN), Hippocampus, Hyperphosphorylated Tau, India, Israel, Italy, β-amyloid, β-Amyloid 1-42 (Aβ42), Japan, Lumbar Puncture Compliance, Lumbar Punctures, Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), Measurement of Treatment Effects, Mexico, Morphometric Analysis, Network-Based Biomarkers, Neurodegeneration, Neurofibrillary Tangles (NFTs), Neuroimaging, Neuroimaging of Dementia, Neuroimaging Tools, o (Orientation), Okayama University, Poland, Positron Emission Tomography (PET), Quintiles, Resting-State fMRI (R-fMRI), South Africa, Spain, Sweden, Tactile Biomarker (tac), Taiwan, Tau Pathology, Tau Protein, Universidad Politécnica de Madrid, USA, Volumetric MRI, w (Word Recognition)
|
Leave a comment
Brain Scans Distinguish Between Dementia Types (BBC News / Neurology)
Summary Scientists at the University of Pennsylvania believe they may have discovered how to distinguish between different types of dementia without the need for invasive lumbar puncture tests to obtain cerebrospinal fluid (csf). Alzheimer’s and frontotemporal dementia share similar features and symptoms and can … Continue reading →
Posted in BBC News, Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, International, Quick Insights, Systematic Reviews, Universal Interest
|
Tagged Alzheimer Precision Medicine (APM) Paris, Amyloid Beta, Amyloid Beta Protein, Assessment and Diagnosis, Azienda sanitaria universitaria integrata di Udine, Beta-Amyloid, Carlo Besta Foundation and Neurological Institute (Milan), Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cochrane Database of Systematic Reviews, CSF, CSF Aβ, CSF Tau, CSF tt/Aβ Ratios, Department of Clinical and Experimental Medicine: University of Pisa, Department of Neurosciences Psychology Drug Research and Child Health (NEUROFARBA), Diagnosis and Assessment, Diagnosis and Screening: Frontotemporal Dementia, Diagnosis of Alzheimer's Disease, Diagnostic Errors, Diagnostic Markers, Dipartimento di Medicina Interna: Azienda sanitaria universitaria integrata di Udine, Dipartimento di Scienze Biomediche e Cliniche "L. Sacco": Università degli Studi di Milano, Early Differential Diagnosis, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Fondazione IRCCS Ca' Granda (Milan), France, Frontotemporal Dementia, Frontotemporal Lobar Degeneration (FTLD), FTLD: Frontotemporal Lobar Degeneration, Italy, β-amyloid, Magnetic Resonance Imaging (MRI), MRI, MRI Scans, Neuroepidemiology Unit: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Ospedale Maggiore Policlinico, Pitié-Salpêtrière Hospital, Sorbonne University, Structural MRI, Switzerland, Systematic Reviews and Meta-Analyses, Tau, Tau Protein, Total Tau (T-tau), Universita' degli studi di Milano, University Hospitals and University of Geneva, University of Florence, University of Pennsylvania, University of Pisa, UOC Pronto Soccorso e Medicina D'Urgenza: Università degli Studi di Milano
|
Leave a comment
People Likely to Develop Alzheimer’s Disease are Potentially Identifiable Ten Years Earlier (Department of Health, Dementia)
[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 7, February 2012]. Summary People at risk of developing Alzheimer’s Disease (AD) could be pre-diagnosed ten years before the disease becomes manifest, according to a … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, National Audit Office, Quick Insights, Universal Interest
|
Tagged Alzheimer’s Early Screening, Amyloid Beta, Amyloid Beta Protein, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, CSF, CSF Aβ, CSF Tau, Early Detection of Alzheimer’s Disease, Early Diagnosis of Alzheimer's Disease, Early Screening, β-Amyloid 1-42 (Aβ42), MCI, MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), Neuropsychiatric Clinic: Skåne University Hospital (Malmö: Sweden), Phosphorylated Tau (P-tau), Skåne University Hospital (Malmö: Sweden), Tau Protein, Test to Detect Early-Stage Alzheimer’s Disease, Total Tau (T-tau)
|
Leave a comment
Biomarkers Predicting Cognitive Decline and Alzheimer’s Disease
[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 3, October 2011]. Summary The process of developing Alzheimer’s Disease is known to begin years before the formal diagnosis of clinical dementia. The concept … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews, Universal Interest
|
Tagged ASYMAD, Asymptomatic Alzheimer’s Disease, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), CSF Aβ, CSF Tau, Early Diagnosis of Alzheimer's Disease, Fluid and Imaging Biomarkers, Metabolic FDG-PET, Molecular PIB-PET, Preclinical Alzheimer's Disease, Structural MRI
|
Leave a comment
